Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Update

Avalo Therapeutics, Inc. (NASDAQ:AVTX) saw a large increase in short interest in February. As of February 28th, there was short interest totalling 90,600 shares, an increase of 19.2% from the February 13th total of 76,000 shares. Approximately 1.1% of the company’s shares are sold short. Based on an average daily volume of 102,400 shares, the short-interest ratio is presently 0.9 days.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Ikarian Capital LLC raised its stake in shares of Avalo Therapeutics by 1,673.0% in the third quarter. Ikarian Capital LLC now owns 970,359 shares of the company’s stock worth $9,218,000 after purchasing an additional 915,629 shares during the last quarter. RA Capital Management L.P. purchased a new stake in shares of Avalo Therapeutics in the third quarter worth approximately $9,186,000. Geode Capital Management LLC raised its stake in shares of Avalo Therapeutics by 937.0% in the fourth quarter. Geode Capital Management LLC now owns 104,853 shares of the company’s stock worth $779,000 after purchasing an additional 94,742 shares during the last quarter. Bank of Montreal Can purchased a new stake in shares of Avalo Therapeutics in the fourth quarter worth approximately $446,000. Finally, Walleye Capital LLC purchased a new stake in shares of Avalo Therapeutics in the fourth quarter worth approximately $145,000. Institutional investors own 87.06% of the company’s stock.

Analyst Upgrades and Downgrades

AVTX has been the topic of several research analyst reports. BTIG Research initiated coverage on Avalo Therapeutics in a research report on Thursday, December 19th. They set a “buy” rating and a $40.00 target price on the stock. Piper Sandler initiated coverage on Avalo Therapeutics in a research report on Friday, February 28th. They set an “overweight” rating and a $48.00 target price on the stock. Finally, Wedbush began coverage on Avalo Therapeutics in a research report on Friday, February 21st. They set an “outperform” rating and a $18.00 target price on the stock. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Avalo Therapeutics has an average rating of “Buy” and an average price target of $35.33.

Avalo Therapeutics Trading Up 2.8 %

Shares of NASDAQ:AVTX opened at $7.99 on Thursday. The business’s 50 day simple moving average is $7.42 and its two-hundred day simple moving average is $9.11. Avalo Therapeutics has a 52-week low of $4.36 and a 52-week high of $34.46.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.